SCHEDULE: Jennison Associates Discloses Tarsus Pharmaceuticals Stake
Ownership Filing
Jennison Associates LLC has reported a 4.0% beneficial ownership of Tarsus Pharmaceuticals Inc. common stock as of March 31, 2026.
Summary
- Jennison Associates LLC has filed a Schedule 13G, indicating their beneficial ownership of Tarsus Pharmaceuticals Inc. common stock.
- As of March 31, 2026, Jennison Associates LLC beneficially owns 1,712,124 shares of Tarsus Pharmaceuticals Inc. common stock.
- This ownership represents 4.0% of the class of securities.
- The filing is an amendment (Amendment No. 1) to a previous filing.
- Jennison Associates LLC is identified as an investment adviser (IA).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake by an institutional investor, which is informative but does not inherently signal positive or negative performance for the company itself.
Positives
- Jennison Associates LLC has taken a significant stake in Tarsus Pharmaceuticals Inc., potentially indicating confidence in the company's future prospects.
- The 4.0% ownership stake is a notable position for an institutional investor.
Future Outlook
This filing does not contain forward-looking statements or guidance from Tarsus Pharmaceuticals Inc. It solely reports on the ownership stake of Jennison Associates LLC.
Industry Context
StockSavvy.ai notes that institutional investor filings like this Schedule 13G are common and provide transparency regarding significant ownership changes. Jennison Associates LLC's filing indicates a substantial investment in Tarsus Pharmaceuticals Inc., which could be influenced by the company's pipeline, clinical trial results, or market positioning within the pharmaceutical sector.
Stakeholder Impact
- Shareholders: The filing provides transparency on a significant institutional investor's stake, which may influence market perception and trading activity.
- Management: The increased visibility of a substantial shareholder may lead to increased engagement and scrutiny from Jennison Associates LLC.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of Event Which Requires Filing of this Statement |
| 05/06/2026 | Date of Certification by Jennison Associates LLC |
Keywords
Tarsus Pharmaceuticals, Jennison Associates LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.